Omics techniques and biobanks to find new biomarkers for the early detection of acute lymphoblastic leukemia in middle-income countries: a perspective from Mexico.

Autor:	Aguirre-Guillén WA; Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, Mexico; Unidad Biológica y de Ciencias de la Salud, Universidad Autónoma Metropolitana, Mexico City, Mexico., Angeles-Floriano T; Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, Mexico; Departamento de Laboratorio Clínico, Hospital Infantil de México Federico Gómez, Mexico City, Mexico., López-Martínez B; Sub-Dirección de Diagnóstico Clínico, Hospital Infantil de México Federico Gómez, Mexico City, Mexico., Reyes-Morales H; Departamento de Investigación, Hospital Infantil de México Federico Gómez, Mexico City, Mexico., Zlotnik A; Department of Physiology and Biophysics and Institute for Immunology, University of California Irvine, Irvine, CA, USA., Valle-Rios R; Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, Mexico; Unidad de investigación Escuela de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: vallerios@gmail.com.
Jazyk:	angličtina
Zdroj:	Boletin medico del Hospital Infantil de Mexico [Bol Med Hosp Infant Mex] 2017 May - Jun; Vol. 74 (3), pp. 227-232. Date of Electronic Publication: 2017 May 24.
DOI:	10.1016/j.bmhimx.2017.03.007
Abstrakt:	Acute lymphoblastic leukemia (ALL) affects the quality of life of many children in the world and particularly in Mexico, where a high incidence has been reported. With a proper financial investment and with well-organized institutions caring for those patients, together with solid platforms to perform high-throughput analyses, we propose the creation of a Mexican repository system of serum and cells from bone marrow and blood samples derived from tissues of pediatric patients with ALL diagnosis. This resource, in combination with omics technologies, particularly proteomics and metabolomics, would allow longitudinal studies, offering an opportunity to design and apply personalized ALL treatments. Importantly, it would accelerate the development of translational science and will lead us to further discoveries, including the identification of new biomarkers for the early detection of leukemia. (Copyright © 2017 Hospital Infantil de México Federico Gómez. Publicado por Masson Doyma México S.A. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu